CDEK
← All drugs Report issue

eptifibatide

Trade name: integrilin

Peptideapproved

Approved

May 18, 1998

Eptifibatide is a platelet aggregation inhibitor - an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. It is a cyclic heptapeptide derived from a protein found in the venom of the southeastern pygmy rattlesnake. It belongs to the class of the so called arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide inhibits platelet aggregation by reversibly binding to the platelet receptor glycoprotein (GP) IIb/IIIa of human platelets, thus preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands. Inhibition of platelet aggregation occurs in a dose- and concentration-dependent manner. It is used for treatment of myocardial infarction and acute coronary syndrome. — NCATS

Clinical trial activity

29 trials · 32 clinical orgs · 21 marketing orgs

Phase 1
3
Phase 2
23
Phase 3
8
Phase 4
5

Earliest trial started May 1, 2003 (NCT00061373)

Timeline

1990s

  1. May 18, 1998

    Schering — Earliest FDA Approval

  2. May 18, 1998

    Schering — NDA Organization

  3. May 18, 1998

    Schering — NDA Secondary Org

  4. May 18, 1998

    Merck — Marketing Organization

  5. May 18, 1998

    Merck — NDA Secondary Org

2000s

  1. Jan 1, 2003

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2003

    Earliest Phase 2 Sponsor(trial)

  3. Jan 1, 2004

    Merck — Earliest Phase 3 Sponsor(trial)

2010s

  1. Jun 5, 2015

    Teva — Marketing Organization

  2. Dec 8, 2015

    Aurobindo Pharma — Marketing Organization

  3. Dec 8, 2015

    Eugia Pharma — Marketing Organization

  4. Dec 8, 2016

    Amneal Pharmaceuticals — Marketing Organization

  5. Apr 18, 2017

    Akorn, Inc. — Marketing Organization

  6. Apr 18, 2017

    Rising Pharmaceuticals — Marketing Organization

  7. Nov 6, 2017

    Accord Research — Marketing Organization

  8. Mar 7, 2018

    Sagent Pharmaceuticals, Inc. — Marketing Organization

  9. Mar 7, 2018

    Nichi-Iko Pharmaceutical Co., Ltd. — Marketing Organization

  10. Jul 20, 2018

    Mylan — Marketing Organization

  11. Nov 23, 2018

    Baxalta — Marketing Organization

  12. Nov 23, 2018

    Shire — Marketing Organization

  13. Jan 25, 2019

    Hainan Poly Pharm — Marketing Organization

  14. Jan 25, 2019

    SLATE RUN PHARMA — Marketing Organization

  15. Mar 11, 2019

    USV — Marketing Organization

2020s

  1. Mar 20, 2020

    Hybio — Marketing Organization

  2. Sep 7, 2021

    Shuangcheng — Marketing Organization

  3. May 9, 2024

    Eu Yan Sang — Marketing Organization

  4. May 9, 2024

    Meitheal — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

Approval history

  • approvedPriority reviewMay 18, 1998

Chemistry & pharmacology

Loading structure…

SMILES

NC(=N)NCCCC[C@@H]1NC(=O)CCSSC[C@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H](CC3=CNC4=C3C=CC=C4)NC(=O)[C@H](CC(O)=O)NC(=O)CNC1=O)C(N)=O
Mol. weight
831.962 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral
Availability
Prescription Only
Multi-specific
No

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • eftifibatide
  • epifibatide
  • epifibratide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • eptifibatide
  • integrelin
  • integrelin
  • integrelin
  • integrelin
  • integrilin
  • integrilin
  • integrilin
  • integrilin
  • integrilin
  • intrifiban
  • intrifiban
  • intrifiban
  • intrifiban

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06712004Phase 2Dec 15, 2024Southern Medical University
NCT05415150Phase 1/Phase 2 (Phase 2)Feb 18, 2022Baylor University
NCT03735979Phase 3Jun 30, 2019National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati
NCT03844594Phase 3Apr 6, 2019Capital Medical University, Government of China
NCT02925923Phase 2Sep 1, 2016University of Alabama, Birmingham
NCT02204852Phase 2Sep 1, 2014University of Copenhagen
NCT01919723Phase 2Feb 1, 2014AstraZeneca, University of Alabama, Birmingham
NCT01977456Phase 2Sep 1, 2013National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati
NCT01532544Phase 2Jun 1, 2012Thrombologic ApS, University of Copenhagen
NCT01522417Phase 2Apr 1, 2012Medicure, SCRI Development Innovations
NCT01076764Phase 3Apr 1, 2010Sanofi
NCT00945308Phase 2Aug 1, 2009Tel Aviv University
NCT00894803Phase 2Jul 1, 2009National Institute of Neurological Disorders and Stroke (NINDS), University of Cincinnati
NCT00834899Phase 1/Phase 2 (Phase 2)Jan 1, 2009University of North Carolina at Chapel Hill
NCT00638976Phase 3Nov 1, 2007Fondazione Mediolanum per Attività e Ricerche Cardiovascolari Onlus
NCT00719914Phase 2Nov 1, 2007Harvard University, Schering-Plough, TIMI Study Group, Boston, MA
NCT01454440Phase 4Oct 1, 2007University of Turin
NCT00812435Phase 3Aug 1, 2007Georgetown University
NCT01103440N/AApr 1, 2007Icahn School of Medicine at Mount Sinai
NCT00426751Phase 3Oct 1, 2006GlaxoSmithKline
Showing 20 of 29 trials
Page 1 / 2

Organizations

Research & Development (32)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
National Institute of Neurological Disorders and Stroke (NINDS)Government5122003
University of CincinnatiAcademic/Hospital4422003
Schering-PloughFor profit3032005
Harvard UniversityAcademic/Hospital2222006
SanofiFor profit2222006
University of Alabama, BirminghamAcademic/Hospital2212014
University of CopenhagenAcademic/Hospital2112012
AstraZenecaFor profit1012014
Baylor UniversityAcademic/Hospital1112022
Capital Medical UniversityAcademic/Hospital1012019
Case Western Reserve UniversityAcademic/Hospital1012006
Duke UniversityAcademic/Hospital1012004
Fondazione Mediolanum per Attività e Ricerche Cardiovascolari OnlusAcademic/Hospital1112007
Georgetown UniversityAcademic/Hospital1112007
GlaxoSmithKlineFor profit1112006
Government of ChinaGovernment1112019
Icahn School of Medicine at Mount SinaiAcademic/Hospital1112007
LifeBridge HealthAcademic/Hospital1112006
MedicureFor profit1112012
MedtronicFor profit1012005
32 organizations
Page 1 / 2

Marketing (24)

OrganizationOrg typeRelationshipDate
Accord ResearchFor profitMKTGNov 6, 2017
Akorn, Inc.For profitMKTGApr 18, 2017
Amneal PharmaceuticalsFor profitMKTGDec 8, 2016
Aurobindo PharmaFor profitMKTGDec 8, 2015
BaxaltaFor profitMKTGNov 23, 2018
Eu Yan SangFor profitMKTGMay 9, 2024
Eugia PharmaFor profitMKTGDec 8, 2015
Hainan Poly PharmFor profitMKTGJan 25, 2019
HybioFor profitMKTGMar 20, 2020
MeithealFor profitMKTGMay 9, 2024
MerckFor profitMKTGMay 18, 1998
MerckFor profitNDA2May 18, 1998
MylanFor profitMKTGJul 20, 2018
Nichi-Iko Pharmaceutical Co., Ltd.For profitMKTGMar 7, 2018
Rising PharmaceuticalsFor profitMKTGApr 18, 2017
SLATE RUN PHARMAFor profitMKTGJan 25, 2019
Sagent Pharmaceuticals, Inc.For profitSYNMar 7, 2018
Sagent Pharmaceuticals, Inc.For profitMKTGMar 7, 2018
ScheringFor profitNDAMay 18, 1998
ScheringFor profitNDA2May 18, 1998
ShireFor profitMKTGNov 23, 2018
ShuangchengFor profitMKTGSep 7, 2021
TevaFor profitMKTGJun 5, 2015
USVFor profitMKTGMar 11, 2019